Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with 201 Tl. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with 201 Tl isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm 3 ) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.
Bibliographical noteFunding Information:
The authors acknowledge the helpful discussions of Miklós Kellermayer (Department of Biophysics and Radiation Biology, Semmelweis University). Dr. Levente Mészáros (King’s College, London) is gratefully acknowledged for valuable contributions in editing and proofing the manuscript. The high value technical support in SPECT/MRI image acquisitions from Mediso (Gábor Németh, Sándor Hóbor) is gratefully acknowledged. The research leading to these results has received funding from the European Union’s Seventh Frame-work Programme (FP7/2007-2013) under Grant Agreements HEALTH-F2-2011-278850 (INMiND), FP7 HEALTH-305311 (INSERT), and TÁMOP-4.2.1./B-09/1/KMR-2010-0001. This study was supported by the National Research, Development and Innovation Office of Hungary (NKFIA; NVKP-16-1-2016-0017 National Heart Program). Krisztián Szigeti was supported by the Janos Bolyai Research Fellowship Program of the Hungarian Academy of Science. Parasuraman Padmanabhan and Balázs Gulyás acknowledge the support from the Lee Kong Chian School of Medicine, Nanyang Technological University Start-Up Grant.
© 2018 Krisztián Szigeti et al.